Ono Pharmaceutical Co., Ltd.

Toshihide Watanabe

Kensuke Kusumi

Yoshikazu Goto

Kousuke Tani

Shinsaku Yamane

Takaki Komiya

Seiji Ogawa

Isamu Sugimoto

Satomi Imaide

Toshimitsu Endo

Naomi Tsuburaya

Kazumi Moriyuki

Yuichi Inagaki

A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1Preceptor relative to the S1Preceptor, and can thus serve as a therapeutic agent for S1P-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

Compounds having S1P5 receptor agonistic activity

Tetrahydronaphthalene derivative

Provided is an EP2 agonist having excellent safety. A compound represented by general formula (I) (wherein all symbols are as defined in the description), a salt or N-oxide of the compound, or a solvate or prodrug of the compound or the salt or N-oxide has an EP2 agonist activity and is highly safe, and is therefore useful as a medicine, particularly a therapeutic agent for diseases associated with EP2 receptors, such as immune diseases, allergic diseases, neuronal death, dysmenorrhea, premature birth, miscarriage, baldness, ocular diseases, erectile dysfunction, arthritis, lung injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, bone diseases and cartilage injury.

Compound having EP2 agonist activity

A compound represented by general formula (I) wherein all symbols are as defined in the specification, a salt or N-oxide of the compound, or a solvate or prodrug of the compound or the salt or N-oxide has a selective EP2 agonist activity and is highly safe, and is therefore useful as a drug, especially as a therapeutic agent for EP2 receptor-related diseases including immune diseases, allergic diseases, neuronal death, dysmenorrhea, premature birth, miscarriage, baldness, ocular diseases, erectile dysfunction, arthritis, lung injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, bone diseases, cartilage injury and others. 

Compound having selective EP2 agonist activity

Growing community of inventors

Osaka, Japan

Toshihide Watanabe